Latest Breaking News On - Intermountain precision genomics - Page 1 : comparemela.com

Liquid Biopsy Market Worth $11 3 billion | MarketsandMarkets

Liquid Biopsy Market Worth $11 3 billion | MarketsandMarkets
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomAashish mehraAsia pacificGuardant healthMesa labs incFreenome holdings incLaboratory corporation of america holdingsCompany typeBio rad laboratories incProduct development innovationRoche ltd switzerlandIntermountain healthBiopsy companiesSysmex corporation japanIllumina inc

Myriad Genetics, Inc (NASDAQ:MYGN) Q1 2024 Earnings Call Transcript

Myriad Genetics, Inc (NASDAQ:MYGN) Q1 2024 Earnings Call Transcript
insidermonkey.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from insidermonkey.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesSalt lake citySalt lakeSouth san franciscoMatt scaloMatthew scaloDoug schenkelDan brennanPuneet soudaMychoice cdxMark verrattiGeorge danekerSam rahaPaul diazBracanalysis cdx

Myriad Genetics Inc (MYGN) Reports 11% Revenue Growth in Q4 and Full-Year 2023

Company Raises 2024 Revenue Guidance and Delivers Positive Adjusted EPS in Q4

Bracanalysis cdxPaulj diazGenetics incDiagnostics researchAnalysis of company performanceCompany overviewPrecise oncology solutionsIntermountain precision genomicsMyriad geneticsMedical diagnosticsMyriad geneticForesight universal plusPrecise tumorMyriad genetics incIntermountain precision genomicsOperating expenses

Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics

SALT LAKE CITY, Feb. 01, 2024 Myriad Genetics, Inc., , a leader in genetic testing and precision medicine, today announced it has completed the acquisition from Intermountain Health of select.

United statesGlenn farrellMatt scaloIntermountain healthExchange commissionGenetics incGlobenewswire incIntermountain precision genomicsTumor testPrecise liquid testPrecise tumor testSolid tumorPrecise tumorPrecise liquidPrivate securities litigation reform actAnnual report

Myriad Genetics Completes Acquisition of Precise Tumor,

SALT LAKE CITY, Feb. 01, 2024 (GLOBE NEWSWIRE) Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today.

United statesMatt scaloGlenn farrellIntermountain healthExchange commissionGenetics incIntermountain precision genomicsTumor testPrecise liquid testPrecise tumor testSolid tumorPrecise tumorPrecise liquidPrivate securities litigation reform actAnnual reportQuarterly reports